Universität zu Köln

Canberk, Sule ORCID: 0000-0002-3736-1323 and Engels, Marianne (2021). Cytology samples and molecular biomarker testing in lung cancer-advantages and challenges. Virchows Arch., 478 (1). S. 45 - 58. NEW YORK: SPRINGER. ISSN 1432-2307

Full text not available from this repository.

Abstract

This review presents an overview on molecular diagnostic in lung cancer using cytologic samples. Every patient with advanced non-small cell lung cancer (NSCLC) should be tested for targetable driver mutations and gene arrangements. If a mutation is found, this may open an option for targeted therapy. As most of the NSCLC patients in advanced stage of disease are no candidates for surgery, these tests have to be performed on small biopsies or cytology samples. The most common and treatable gene alterations should be tested in every patient: EGFR, ALK, ROS1. A growing number of other genetic changes with targetable mutations may become treatable in the near future. To find patients who might profit from inclusion into clinical studies, relevant additional markers may be tested in an appropriate context. Another important approach for treatment is immunotherapy of lung cancer, which is guided by status of PD-L1 expression on tumour cells. The use of cytology samples carries considerable advantages: often, DNA of high quality is extracted thus enabling easy and precise analysis, and samples may be easily obtained. In case of effusions, effusion fluid seldom is not aspirated for immediate patient relief, so no additional dedicated procedure is needed. Some challenges exist: If the tumour cell count is low, mutations with a low allelic frequency may be missed. In cellblocks formalin-induced DNA, damage may obviate any DNA analysis. In very cellular smears, FISH may be impossible due to massive overlapping of nuclei. Autofluorescence may impede FISH analysis. Although there is no real universal test for genomic profiling for lung cancer, the pathology laboratory must be prepared to offer different assays on different specimens in order to address turnaround time and optimise detections of difficult tumour alterations such as gene fusions. The data from the literature demonstrate that cytology show consistent results, and it is a good alternative for lung cancer molecular testing.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Canberk, Sule UNSPECIFIED orcid.org/0000-0002-3736-1323 UNSPECIFIED Engels, Marianne UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-580982
DOI:	10.1007/s00428-020-02995-2
Journal or Publication Title:	Virchows Arch.
Volume:	478
Number:	1
Page Range:	S. 45 - 58
Date:	2021
Publisher:	SPRINGER
Place of Publication:	NEW YORK
ISSN:	1432-2307
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language IN-SITU HYBRIDIZATION; BRAF MUTATIONS; SPECIMENS; DIAGNOSIS; CYTOPATHOLOGY; GUIDELINE; PATHOLOGY; IMMUNOHISTOCHEMISTRY; RECOMMENDATIONS; SELECTION Multiple languages Pathology Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/58098